Why does re‑bleeding occur at the beginning of week 3 of Feirza (combined estrogen‑progestin oral contraceptive)?

Re-bleeding at Week 3 of Feirza: Hormone Withdrawal Phenomenon

Re-bleeding at the beginning of week 3 of Feirza occurs because you are entering the hormone-free interval (the brown placebo tablets), which triggers withdrawal bleeding due to the sudden drop in estrogen and progestin levels. This is the expected mechanism of action for cyclic combined oral contraceptives.

Understanding the Timing

Feirza follows a 21/7 regimen:

• Weeks 1-3: 21 white-to-off-white active tablets containing norethindrone acetate and ethinyl estradiol
• Week 4: 7 brown placebo tablets (containing only ferrous fumarate, no hormones)

According to the FDA label, menstruation usually begins 2-3 days after starting the brown tablets, but may begin as late as the 4th or 5th day 1. This timing corresponds to the beginning of week 3 transitioning into week 4, when hormone levels drop precipitously.

Why This Happens

Physiologic Mechanism

The endometrium builds up during the 21 days of active hormone exposure. When you transition to the hormone-free interval (brown tablets), the sudden withdrawal of hormonal support causes endometrial destabilization and shedding, resulting in withdrawal bleeding 2.

This is NOT Breakthrough Bleeding

It's critical to distinguish this from true breakthrough bleeding:

• Withdrawal bleeding = Expected bleeding during hormone-free interval
• Breakthrough bleeding (BTB) = Unscheduled bleeding during active hormone administration (weeks 1-3 on white tablets) 3

Clinical Implications

When to Reassure vs. Investigate

Reassure the patient if:

• Bleeding starts 2-5 days after beginning brown tablets
• This is their normal pattern
• No other concerning symptoms present

Investigate further if 2:

• Bleeding occurs during active white tablet weeks (true BTB)
• Patient missed doses (most common cause of unscheduled bleeding)
• Bleeding pattern changes significantly
• Associated symptoms suggest:
  • Pregnancy (if non-adherent to regimen)
  • STD
  • Drug interactions (enzyme inducers like rifampin, anticonvulsants)
  • Smoking (increases BTB risk)
  • New pathologic uterine conditions (polyps, fibroids)

Management Approach

If bleeding is problematic during the hormone-free interval:

1. First, exclude pathology - Rule out pregnancy, infection, structural lesions if clinically indicated 2, 4

2. Verify adherence - Non-compliance is the most common cause of abnormal bleeding patterns 5

3. Consider formulation adjustment if withdrawal bleeding is excessively heavy:

   • Some patients may benefit from shortening the hormone-free interval (though this requires switching to a different formulation)
   • Increasing estrogen content from 20 mcg to 30-35 mcg may provide better endometrial stability 6, 7

Common Pitfalls to Avoid

• Don't confuse withdrawal bleeding with breakthrough bleeding - They have different causes and management strategies
• Don't immediately change contraception - This is expected physiology with cyclic COCs
• Don't forget to counsel at initiation - Setting expectations about bleeding patterns improves adherence 2, 3
• Don't overlook missed pills - This is the #1 cause of unscheduled bleeding 5

Key Counseling Points

Per FDA labeling, patients should understand that 1:

• Bleeding typically starts 2-3 days after beginning brown tablets
• The next pack should be started on schedule regardless of whether bleeding has stopped
• Reduced flow or absence of bleeding after several months is not necessarily concerning and doesn't indicate pregnancy if pills were taken correctly
• If two consecutive periods are missed, pregnancy should be ruled out before continuing

The timing you're describing—bleeding at the start of week 3—likely represents either early withdrawal bleeding (if transitioning to brown tablets) or breakthrough bleeding if still on active white tablets. The distinction matters for management.